Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
475.2 INR | -0.66% | -2.69% | +13.06% |
06-17 | Fortis, Apollo, Medanta, and Max Lead the Charge in Bidding War for Jaypee Healthcare | CI |
06-11 | Fortis Healthcare Limited Announces Executive Appointments | CI |
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 59.29 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+13.06% | 4.31B | B- | ||
-34.77% | 13.2B | B+ | ||
+4.48% | 11.76B | B+ | ||
-3.60% | 11.57B | B | ||
+8.44% | 10.67B | B+ | ||
+28.58% | 8.64B | B | ||
-9.79% | 7.24B | A- | ||
+10.23% | 6.98B | B- | ||
+8.41% | 6.46B | D | ||
0.00% | 4.99B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FORTIS Stock
- FORTIS Stock
- Ratings Fortis Healthcare Limited